Vivus

Business briefs: Layoffs at Roche and Merck, plus pipeline news

Merck and Roche Diagnostics announce job cuts; Novartis abandons an Afinitor study; an FDA advisory committee gives Bayer's lung drug the nod; Vivus still has no plans for Qsymia DTC; and Isis drops development of a mid-stage RA drug

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.